Johnson & Johnson (JNJ) 123.00 $JNJ
Pfizer (PFE) Gets FDA Nod for Label Expansion of Prevnar 13
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 8:25AM CDT
Pfizer Inc. (PFE) announced that the FDA has approved a label expansion of vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]).
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07)
Sucampo to Stop Developing Cobiprostone for Oral Mucositis
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:28PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) announced that it will discontinue the development of its pipeline candidate, cobiprostone.
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), SCMP: 11.32 (-0.01)
Shire's (SHPG) Dry Eye Disease Drug Xiidra Gets FDA Nod
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:20PM CDT
Shire plc (SHPG) received a major boost when the FDA approved its ophthalmology drug Xiidra for the treatment of the signs and symptoms of dry eye disease in adults.
JNJ: 123.00 (+0.08), SHPG: 192.49 (-2.82), PFE: 36.31 (+0.07)
Lower-cost biotech drug gets thumbs up from FDA panel
By MATTHEW PERRONE - AP - Tue Jul 12, 4:39PM CDT
WASHINGTON (AP) — The second-biggest selling drug in the world could get some cheaper competition in the U.S., after a federal panel endorsed an alternative version of the pricey medication used to treat rheumatoid arthritis and other inflammatory diseases.
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), AMGN: 160.52 (-1.44)
Zacks Industry Outlook Highlights: Edwards Lifesciences, Medtronic and Johnson & Johnson
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 8:30AM CDT
Zacks Industry Outlook Highlights: Edwards Lifesciences, Medtronic and Johnson & Johnson
JNJ: 123.00 (+0.08), MDT: 88.75 (-0.17), EW: 106.49 (+0.22)
MedTech Industry Stock Outlook - July 2016
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 5:08PM CDT
MedTech Industry Stock Outlook - July 2016
JNJ: 123.00 (+0.08), MDT: 88.75 (-0.17), EW: 106.49 (+0.22)
JNJ VS. PFE: Which Is The Better Large Cap Pharma Stock?
Adam Clark - Zacks Investment Research - Mon Jul 11, 12:06PM CDT
Operating in an industry ranked in the top 10% of all industries by Zacks and both stocks sporting a Zacks Rank #2 (Buy), Johnson&Johnson and Pfizer Inc. should both be getting looked at from investors right now, but which is the better buy?
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07)
Shire (SHPG) Gets EU Nod for Label Expansion of Revestive
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:36PM CDT
Shire plc (SHPG) announced that the European Commission has granted an extension of the market authorization for its gastrointestinal drug (GI) Revestive for use in the pediatric population.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), SHPG: 192.49 (-2.82), PFE: 36.31 (+0.07)
Roche Asthma Drug Xolair Gets FDA Nod for Label Expansion
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:23PM CDT
Roche Holding AG (RHHBY) announced that the FDA has approved a label expansion of respiratory drug, Xolair.
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), NVS: 82.03 (+0.35)
Next Resistance Level for Johnson & Johnson (JNJ) is $123.24
Comtex SmarTrend(R) - Fri Jul 08, 8:39AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) opened today above their pivot of $122.44 and have already reached the first level of resistance at $122.88. Should the shares continue to rise, the resistance pivots of $123.24 and $124.04 will be of interest.
JNJ: 123.00 (+0.08)
Seattle Genetics/Takeda Adectris' Label Expanded in the EU
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 5:21PM CDT
Seattle Genetics, Inc. (SGEN) announced that its partner Takeda Pharmaceutical Company Limited (TKPYY) has received marketing authorization for the label expansion of its lymphoma drug, Adcetris.
JNJ: 123.00 (+0.08), SGEN: 41.32 (-1.22), PFE: 36.31 (+0.07)
Johnson & Johnson Up 19.4% Since SmarTrend Uptrend Call (JNJ)
Comtex SmarTrend(R) - Thu Jul 07, 1:55PM CDT
SmarTrend identified an Uptrend for Johnson & Johnson (NYSE:JNJ) on January 28th, 2016 at $102.45. In approximately 5 months, Johnson & Johnson has returned 19.35% as of today's recent price of $122.27.
JNJ: 123.00 (+0.08)
Abbott Labs' Absorb Stent Gets Regulatory Approval in U.S.
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:58AM CDT
Abbott Laboratories (ABT) received a major boost when the FDA approved its bioresorbable heart stent, Absorb, for the treatment of coronary artery disease in the U.S.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), STJ: 80.45 (-0.43)
Medical Device Consolidation Frenzy: Here's How to Play it
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:00AM CDT
The medical device majors struggling with their core businesses are often on the lookout for emerging therapies through acquisitions and alliances.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), ZBH: 125.57 (+0.11), LDRH: 36.98 (-0.02), MDT: 88.75 (-0.17), TMO: 154.80 (+0.42), STJ: 80.45 (-0.43), HTWR: 57.64 (-0.04), XRAY: 62.98 (-0.15), NUVA: 61.42 (+0.42), FEIC: 106.68 (-0.09)
Texas Federal Court Rules DePuy Hip Implant Trials in Dallas Will Proceed
PR Newswire - Wed Jul 06, 12:18PM CDT
A federal judge in Dallas has cleared the way for a September trial in the ongoing multidistrict litigation filed against DePuy Orthopaedics Inc., a subsidiary of Johnson & Johnson (NYSE: JNJ), by patients who suffered medical problems after receiving the company's Pinnacle metal-on-metal hip implants.
JNJ: 123.00 (+0.08)
UCB's Vimpat Approved in Japan for Partial Onset Seizures
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:47AM CDT
UCB (UCBJF) and Daiichi Sankyo announced that Vimpat was approved in Japan as an adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy.
JNJ: 123.00 (+0.08), ABBV: 64.77 (-0.73), NVS: 82.03 (+0.35)
Smiles for Soldiers Campaign Encourages Young People to Show Appreciation for Military Service Members
PR Newswire - Wed Jul 06, 9:30AM CDT
Beyond everything they do to keep us safe, service members make the additional sacrifice of spending long periods of time away from family and friends. They miss their families, miss their communities, and certainly, they miss the comforts of home. That's why DoSomething.org, the largest organization for young people and social change has teamed up with Johnson & Johnson for a campaign called Smiles for Soldiers.
JNJ: 123.00 (+0.08)
Cooper Companies Strong on Portfolio Expansion Plans
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 8:38AM CDT
The Cooper Companies Inc. (COO) is firing on all cylinders, buoyed by its expanding product portfolio and consistent earnings results.
BSX: 23.63 (-0.01), JNJ: 123.00 (+0.08), BEAT: 17.35 (-0.44), COO: 178.83 (+0.29)
After Yesterday's Rally of 1.38% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Jul 05, 12:07PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $121.34 to a high of $123.23. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $121.54 on volume of 4.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
JNJ: 123.00 (+0.08)
Dow 30 Stock Roundup: Nike Beats on Earnings, AmEx Raises Dividend
Swarup Gupta - Zacks Investment Research - Mon Jul 04, 8:43AM CDT
The Dow staged a spectacular rebound last week following losses after a surprise Brexit verdict.
JNJ: 123.00 (+0.08), GE: 32.36 (+0.10), MDLZ: 45.60 (-0.13), GS: 157.92 (+1.00), AXP: 63.10 (+0.10), NKE: 57.99 (-0.07), HSY: 108.33 (-0.41), ABBV: 64.77 (-0.73), INTC: 35.01 (+0.07), CSCO: 29.75 (+0.14)
Pfizer (PFE) Gets FDA Nod for Label Expansion of Prevnar 13
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 8:25AM CDT
Pfizer Inc. (PFE) announced that the FDA has approved a label expansion of vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]).
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07)
Sucampo to Stop Developing Cobiprostone for Oral Mucositis
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:28PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) announced that it will discontinue the development of its pipeline candidate, cobiprostone.
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), SCMP: 11.32 (-0.01)
Shire's (SHPG) Dry Eye Disease Drug Xiidra Gets FDA Nod
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:20PM CDT
Shire plc (SHPG) received a major boost when the FDA approved its ophthalmology drug Xiidra for the treatment of the signs and symptoms of dry eye disease in adults.
JNJ: 123.00 (+0.08), SHPG: 192.49 (-2.82), PFE: 36.31 (+0.07)
Lower-cost biotech drug gets thumbs up from FDA panel
By MATTHEW PERRONE - AP - Tue Jul 12, 4:39PM CDT
WASHINGTON (AP) — The second-biggest selling drug in the world could get some cheaper competition in the U.S., after a federal panel endorsed an alternative version of the pricey medication used to treat rheumatoid arthritis and other inflammatory diseases.
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), AMGN: 160.52 (-1.44)
Zacks Industry Outlook Highlights: Edwards Lifesciences, Medtronic and Johnson & Johnson
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 8:30AM CDT
Zacks Industry Outlook Highlights: Edwards Lifesciences, Medtronic and Johnson & Johnson
JNJ: 123.00 (+0.08), MDT: 88.75 (-0.17), EW: 106.49 (+0.22)
MedTech Industry Stock Outlook - July 2016
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 5:08PM CDT
MedTech Industry Stock Outlook - July 2016
JNJ: 123.00 (+0.08), MDT: 88.75 (-0.17), EW: 106.49 (+0.22)
JNJ VS. PFE: Which Is The Better Large Cap Pharma Stock?
Adam Clark - Zacks Investment Research - Mon Jul 11, 12:06PM CDT
Operating in an industry ranked in the top 10% of all industries by Zacks and both stocks sporting a Zacks Rank #2 (Buy), Johnson&Johnson and Pfizer Inc. should both be getting looked at from investors right now, but which is the better buy?
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07)
Shire (SHPG) Gets EU Nod for Label Expansion of Revestive
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:36PM CDT
Shire plc (SHPG) announced that the European Commission has granted an extension of the market authorization for its gastrointestinal drug (GI) Revestive for use in the pediatric population.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), SHPG: 192.49 (-2.82), PFE: 36.31 (+0.07)
Roche Asthma Drug Xolair Gets FDA Nod for Label Expansion
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:23PM CDT
Roche Holding AG (RHHBY) announced that the FDA has approved a label expansion of respiratory drug, Xolair.
JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), NVS: 82.03 (+0.35)
Next Resistance Level for Johnson & Johnson (JNJ) is $123.24
Comtex SmarTrend(R) - Fri Jul 08, 8:39AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) opened today above their pivot of $122.44 and have already reached the first level of resistance at $122.88. Should the shares continue to rise, the resistance pivots of $123.24 and $124.04 will be of interest.
JNJ: 123.00 (+0.08)
Seattle Genetics/Takeda Adectris' Label Expanded in the EU
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 5:21PM CDT
Seattle Genetics, Inc. (SGEN) announced that its partner Takeda Pharmaceutical Company Limited (TKPYY) has received marketing authorization for the label expansion of its lymphoma drug, Adcetris.
JNJ: 123.00 (+0.08), SGEN: 41.32 (-1.22), PFE: 36.31 (+0.07)
Johnson & Johnson Up 19.4% Since SmarTrend Uptrend Call (JNJ)
Comtex SmarTrend(R) - Thu Jul 07, 1:55PM CDT
SmarTrend identified an Uptrend for Johnson & Johnson (NYSE:JNJ) on January 28th, 2016 at $102.45. In approximately 5 months, Johnson & Johnson has returned 19.35% as of today's recent price of $122.27.
JNJ: 123.00 (+0.08)
Abbott Labs' Absorb Stent Gets Regulatory Approval in U.S.
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:58AM CDT
Abbott Laboratories (ABT) received a major boost when the FDA approved its bioresorbable heart stent, Absorb, for the treatment of coronary artery disease in the U.S.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), STJ: 80.45 (-0.43)
Medical Device Consolidation Frenzy: Here's How to Play it
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:00AM CDT
The medical device majors struggling with their core businesses are often on the lookout for emerging therapies through acquisitions and alliances.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), ZBH: 125.57 (+0.11), LDRH: 36.98 (-0.02), MDT: 88.75 (-0.17), TMO: 154.80 (+0.42), STJ: 80.45 (-0.43), HTWR: 57.64 (-0.04), XRAY: 62.98 (-0.15), NUVA: 61.42 (+0.42), FEIC: 106.68 (-0.09)
Texas Federal Court Rules DePuy Hip Implant Trials in Dallas Will Proceed
PR Newswire - Wed Jul 06, 12:18PM CDT
A federal judge in Dallas has cleared the way for a September trial in the ongoing multidistrict litigation filed against DePuy Orthopaedics Inc., a subsidiary of Johnson & Johnson (NYSE: JNJ), by patients who suffered medical problems after receiving the company's Pinnacle metal-on-metal hip implants.
JNJ: 123.00 (+0.08)
UCB's Vimpat Approved in Japan for Partial Onset Seizures
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:47AM CDT
UCB (UCBJF) and Daiichi Sankyo announced that Vimpat was approved in Japan as an adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy.
JNJ: 123.00 (+0.08), ABBV: 64.77 (-0.73), NVS: 82.03 (+0.35)
Smiles for Soldiers Campaign Encourages Young People to Show Appreciation for Military Service Members
PR Newswire - Wed Jul 06, 9:30AM CDT
Beyond everything they do to keep us safe, service members make the additional sacrifice of spending long periods of time away from family and friends. They miss their families, miss their communities, and certainly, they miss the comforts of home. That's why DoSomething.org, the largest organization for young people and social change has teamed up with Johnson & Johnson for a campaign called Smiles for Soldiers.
JNJ: 123.00 (+0.08)
Cooper Companies Strong on Portfolio Expansion Plans
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 8:38AM CDT
The Cooper Companies Inc. (COO) is firing on all cylinders, buoyed by its expanding product portfolio and consistent earnings results.
BSX: 23.63 (-0.01), JNJ: 123.00 (+0.08), BEAT: 17.35 (-0.44), COO: 178.83 (+0.29)
After Yesterday's Rally of 1.38% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Jul 05, 12:07PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $121.34 to a high of $123.23. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $121.54 on volume of 4.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
JNJ: 123.00 (+0.08)
Dow 30 Stock Roundup: Nike Beats on Earnings, AmEx Raises Dividend
Swarup Gupta - Zacks Investment Research - Mon Jul 04, 8:43AM CDT
The Dow staged a spectacular rebound last week following losses after a surprise Brexit verdict.
JNJ: 123.00 (+0.08), GE: 32.36 (+0.10), MDLZ: 45.60 (-0.13), GS: 157.92 (+1.00), AXP: 63.10 (+0.10), NKE: 57.99 (-0.07), HSY: 108.33 (-0.41), ABBV: 64.77 (-0.73), INTC: 35.01 (+0.07), CSCO: 29.75 (+0.14)
